

# Supporting Information

Morita et al. 10.1073/pnas.1005938107

## SI Materials and Methods

**Cell Cultures.** HeLa, 293T, GHD-1, and HOS cells were maintained in DMEM supplemented with 10% FCS. For immunofluorescence experiments, HeLa or GHD-1 cells were seeded onto coverslips and transfected with siRNA at 30–50% confluence.

**Expression Vectors.** Expression vectors used in these studies are summarized in [Table S2](#).

**siRNA Design and Testing.** The sequences of all siRNA constructs used in this study are provided in [Table S1](#). siRNA target sequences (19nt+d(TT) overhangs) were designed using the Dharmacon siDESIGN Center (Thermo Fisher Scientific Inc.). siRNAs used against VPS4A and VPS4B were designed, validated, and reported previously (1). Between 4 and 10 siRNAs that targeted each ESCRT-III protein were tested for efficacy and specificity ([Fig. S1](#) and [Table S1](#)). Antibodies against both human VPS4 proteins and all human ESCRT-III proteins were obtained or developed ([Table S3](#)) and used in Western blots to determine the efficacy of target protein depletion. However, antibodies against CHMP4C did not detect the endogenous protein, apparently owing to low affinity and/or low protein levels, and the efficacy of CHMP4C silencing was therefore tested using exogenously expressed, epitope-tagged protein. Where appropriate, siRNA specificities were tested by examining the levels of related ESCRT-III family members ([Fig. S1](#)). The following criteria were used to select siRNAs for further study: (i) efficient silencing of the target protein, (ii) target protein specificity (in cases where human ESCRT-III families have multiple family members), and (iii) maximal cell division phenotypes. Red asterisks in [Figs. S1](#) and [S3](#) and [Table S1](#) denote siRNAs that were used to obtain the data reported in the paper. Note that (i) In two cases, siRNAs against a targeted protein also depleted another family member to some degree (CHMP4B siRNA 617 and VPS4B siRNA 1191), and (ii) in every case, the reported phenotypes were reproduced using a second, different siRNA against each target protein (black asterisks in [Figs. S1](#) and [S3](#) and [Table S1](#)). Data from both siRNAs against CHMP2A are reported in [Fig. S3](#) to demonstrate that the unusual phenotype observed upon CHMP2A depletion was observed for multiple different siRNAs. Note, however, that the second siRNA against CHMP2A yielded a higher percentage of cells with multiple centrosomes (similar to the phenotype seen for VPS4B depletion), in addition to the monopolar phenotype observed for the first siRNA. This observation suggests that these two phenotypes may be closely linked. The effects of depleting VPS4B were tested in four different human cell types (HeLa, GHD-1, 293T, and HOS). Similar phenotypes were observed in every cell type, but the phenotypes were more penetrant in HeLa ([Figs. 1–3](#)) and GHD-1 ([Fig. S5 A–C](#)), than in 293T and HOS cells ([Fig. S5A](#)).

**siRNA Transfections.** HeLa, GHD-1, 293T, or HOS cells in 6-well plates (2-mL culture volume) or 12-well plates (containing glass coverslips for microscopy experiments) (1-mL culture volume) were transfected twice with 20-nM siRNA duplexes at 24-h intervals using Lipofectamine RNAi MAX. Cells were harvested and analyzed after an additional 24 h except where specifically noted.

**Antibody Production.** Antibody sources and working dilutions are summarized in [Tables S3](#) and [S4](#). Antibodies against pure recombinant CHMP1B, CHMP2A, and CHMP3 proteins expressed in *E. coli* were raised in New Zealand White Rabbits (Covance, Inc.). Details of ESCRT-III protein expression, purification, and characterization have been described (2).

**Immunofluorescence of Fixed Cells.** siRNA-treated HeLa or GHD-1 cells were fixed with 3% paraformaldehyde (10 min, 25 °C) or 100% methanol (10 min, –20 °C for samples stained with anti- $\gamma$ -Tubulin or anti-Aurora A antibodies). Fixed cells were incubated for greater than 2 h with primary antibodies diluted in PBS containing 0.1% Triton X-100 (PBST) and 3% BSA. Antibody dilutions and associated fixation methods are given in [Table S4](#). Cells were washed 3 times with PBST, incubated with secondary antibodies (diluted in PBST with 3% BSA, 2 h, 25 °C) and/or with SYTOX Green (1  $\mu$ M; Invitrogen) and then washed 3 times with PBST. Alexafluor488, 594, 647, or SYTOX Green signals were detected using a FV300 IX81 confocal microscope (Olympus) with 488-, 543-, and 633-nm excitation wavelengths. Note that VPS4A ([Fig. 5](#)), VPS4B ([Fig. S6](#)), and IST1 (3) all exhibited similar localization patterns. Analogous studies were not performed for other ESCRT-III proteins because our antibodies were not of sufficient quality to localize the endogenous proteins reliably and because terminal tags/fusion constructs typically inactivate ESCRT-III proteins (4, 5).

**Flow Cytometry Analyses of Cellular DNA Content.** Following siRNA treatment, HeLa, 293T, HOS, or GHD-1 cells were treated with trypsin, collected, and resuspended in 0.3 mL PI solution (50  $\mu$ g PI/mL in PBS, 0.1% Triton X100, 0.25 mg RNase/mL, 30 min). Ten thousand PI-positive cells were counted with a FACScan fluorescence-activated cell sorter (FACScan; BD Bioscience), and peak volumes were analyzed using Modifit LT v2.0 software. Results shown in [Fig. 1B](#) represent the average of two experiments, and the error bars show ranges. Results shown in [Fig. S5A](#) represent the mean of three experiments  $\pm$  SD.

**Cell Death Assay.** Following siRNA treatment, HeLa cell morphology was analyzed by light microscopy. Cells with highly convoluted/blebbed plasma membranes were judged to be undergoing cell death, whereas tightly adhered, flat cells or smooth, rounded cells were judged to be normal. Results shown in [Fig. S5D](#) represent the average of two experiments, and the error bars show ranges.

**Time-Lapse Imaging of Living Cells.** HeLa cells stably expressing YFP- $\alpha$ -Tubulin and H2B-mCherry were created by transduction with MLV-based retroviral vectors [pQCXIN; BD Bioscience (Clontech)] that expressed the two fluorescent fusion proteins. Vector stocks were created by cotransfecting the packagable pQC-YFP- $\alpha$ -Tubulin or pQC-H2B-mCherry expression vectors (6  $\mu$ g) with expression vectors for Gag-Pol (PGag-Pol, 4  $\mu$ g) and the VSV-G envelope [pMD.G envelope, 2  $\mu$ g (6)] into 293T producer cells ( $3 \times 10^6$  cells/10-cm dish) using polyethylenimine (PEI). 36 h post-transfection, vector-containing supernatants were harvested and filtered (0.45  $\mu$ m) (Millipore).

HeLa cells ( $2 \times 10^6$  cells/10 cm dish) were then incubated for 12 h with 5 mL of vector-containing culture media supplemented with polybrene (8  $\mu$ g/mL). Following sequential transductions with the YFP- $\alpha$ -Tubulin and H2B-mCherry vectors, YFP- and mCherry-positive cells were sorted by FACS Vantage SE High Speed Cell Sorter (BD Bioscience); >95% of purified cells expressed both YFP- $\alpha$ -Tubulin and H2B-mCherry. These cells were then replated [ $2 \times 10^4$  cells/well in a four-well Lab-Tek II chambered coverglass (Nalge Nunc International)], and incubated at 37 °C with 5% CO<sub>2</sub>. Cells were transfected twice with siRNAs against ALIX, VPS4B, CHMP2A, or with a control siRNA (20 nM, Lipofectamine RNAi Max; Invitrogen). Immediately following the second siRNA transfection, cells were imaged within an Oko lab microscope chamber

(37 °C, 5% CO<sub>2</sub>) using an Olympus IX81 microscope (Orca ER CCD; Hamamatsu and Motorized XY stage; Prior Scientific), UPLANSAPO 40× NA 0.90 objective, using YFP (2427A) and mCherry (TRITC-A) filters (Semrock). Images were acquired every three minutes using the MetaMorph v7.02 software (Molecular Devices Corp.).

**Quantification of Defects in Mitosis and Cytokinesis.** Data shown in Figs. 2 B and C and 3 B, D, and E and Figs. S3B and S5 B–C are the averages from three experiments, ± SD. ≥100 cells were analyzed in each experiment, except for the data in Fig. 2 B and C and Fig. S3B, where fewer cells were counted.

**Cells with multiple and fragmented nuclei.** Cells were stained with SYTOX Green to visualize the DNA/nuclei and were scored as having fragmented nuclei if they had multiple small or interconnected nuclei (Fig. 2A, example #3) or as multinucleated if they had multiple nuclei of normal size (see example #1).

**Midbodies.** Cells were stained with anti- $\alpha$ -Tubulin to facilitate the identification of cells that were connected by midbodies (Fig. 2A, example #2).

**Unaligned chromosomes.** Cells were judged to be in mitosis with unaligned chromosomes if (i) chromosomes were condensed but not aligned along at the metaphase plate (SYTOX Green staining), (ii) phase contrast images showed that the cells were “rounded up” (e.g., see the cell in Fig. 4 panel 1, column 3 at the 33–87 min time points), and (iii) cells were not apoptotic as judged by nuclear and cellular morphology.

**Centrosome number.** Cells were stained with anti-Pericentrin (a centrosomal marker) and the numbers of centrosomes per cell were counted. Note that in ALIX- and CHMP3-depleted cells, centrosomes were only counted in cells that had single nuclei. This procedure was used because the majority of the cells in these cultures were multinuclear (4C-16C DNA content), and therefore had multiple centrosomes because they failed to complete abscission (rather than owing to aberrant centrosomal amplification events). During interphase, control cells typically had two distinct centrosomes (red puncta in Fig. 3A Top Left), with only small

percentages of cells exhibiting single or multiple centrosomes per cell (see quantification in Fig. 3B).


**Centrosome volume.** Centrosomes in anti-Pericentrin stained HeLa cells were reconstructed in 3D from thin Z-stacked confocal images (0.2- $\mu$ m slices). Centrosome reconstructions and volumes were calculated using the Volocity 3D Imaging software (Improvision, Inc.). At least 40 centrosomes were reconstructed for each condition, and measured volumes were binned in multiples of 0.25  $\mu$ m<sup>3</sup> (Fig. 3C).

**Quantification of time-lapse movies.** Measurements for Fig. 4 C–E were made from time-lapse movies of living HeLa cells that expressed YFP- $\alpha$ -Tubulin and H2B-mCherry. Measurements were averaged from three different experiments (± SD), and the total number of measurements made in each case is given within the graphs of Fig. 4. To compile the data shown in Fig. 4C, the duration of mitosis was measured as the time interval between initiation of chromosome condensation and chromosome segregation. In Fig. 4D, mitosis was judged to have failed if visual inspection clearly revealed improper chromosome alignment and segregation, including asymmetric segregation into daughter cells. Finally, in Fig. 4E, abscission was judged to have failed if the cleavage furrow or midbody dissolved and the nascent daughter cells coalesced back into a single cell with multiple or fragmented nuclei. Note that cells lacking ALIX, VPS4B, or CHMP2A also underwent apoptosis somewhat more frequently than control cells (Fig. S5D).

**Time-Course of Centrosome Amplification.** HeLa cells were seeded onto coverslips in a 12-well dish and transfected with siRNA against VPS4B or an irrelevant control as described above. Samples were fixed in methanol every 6 h beginning with the first transfection ( $t = 0$  h), continuing through the second transfection ( $t = 24$  h), and concluding 66 h from the first transfection. Cells were stained with anti-Pericentrin and anti- $\gamma$ -Tubulin antibodies, and the number of centrosomes was counted by microscopy. Mitotic and interphase cells were counted separately, and only those structures that stained with both antibodies were counted as centrosomes. Three counts of 100 cells each were averaged ± SD.


1. Kieffer C, et al. (2008) Two distinct modes of ESCRT-III recognition are required for VPS4 functions in lysosomal protein targeting and HIV-1 budding. *Dev Cell* 15:62–73.
2. Bajorek M, et al. (2009) Structural basis for ESCRT-III protein autoinhibition. *Nat Struct Mol Biol* 16:754–762.
3. Bajorek M, et al. (2009) Biochemical analyses of human IST1 and its function in cytokinesis. *Mol Biol Cell* 20:1360–1373.

4. Howard TL, Stauffer DR, Degnin CR, Hollenberg SM (2001) CHMP1 functions as a member of a newly defined family of vesicle trafficking proteins. *J Cell Sci* 114:2395–2404.
5. von Schwedler UK, et al. (2003) The protein network of HIV budding. *Cell* 114:701–713.
6. Onishi M, et al. (1996) Applications of retrovirus-mediated expression cloning. *Exp Hematol* 24:324–329.



**Fig. S1.** siRNA depletion of ESCRT-III and VPS4 proteins. (A–H) Western blots showing protein levels in cells treated with siRNA to deplete endogenously expressed ESCRT-III and VPS4 proteins (A–C, E–H, and D Upper two panels); anti-ESCRT-III or -VPS4 antibodies) or exogenously expressed CHMP4C-FOS (D Bottom panel, anti-FLAG). Antibodies are identified to the left of each blot, and  $\alpha$ -Tubulin and/or  $\alpha$ -Actin were used as loading controls. The first one or two lanes in each blot show protein levels in cells treated with irrelevant siRNAs. Subsequent lanes show cells treated with siRNAs designed to deplete the designated proteins. Numbers denote the first nucleotide of the siRNA target site within the coding region of the target mRNA, and siRNA sequences are provided in Table S1. (A) CHMP1A/B, (B) CHMP2A/B, (D) CHMP4A/B/C, and (H) VPS4A/B demonstrate that siRNAs against one ESCRT-III/VPS4 family member generally did not deplete related family members, although the CHMP4B<sub>617</sub> siRNA partially depleted CHMP4A, and VPS4B<sub>1191</sub> depleted VPS4A. siRNAs were also tested for toxicity by coexpressing another gene product (HIV-Gag) and assaying its expression level. Asterisks indicate siRNAs that were chosen for further study: red asterisks designate siRNAs used in all figures within the main paper, and black asterisks designate siRNAs used to confirm each phenotype (e.g., Fig. S3). Relevant ESCRT-III proteins are denoted by closed arrows.





**Fig. S4.** Confirmation of centrosomal staining. (A) Confocal images of interphase HeLa cells stained for two centrosomal markers (mouse anti- $\gamma$ -Tubulin, green, *Left*; and rabbit anti-Pericentrin, red, *Center*; with the two images overlaid, *Right*). Costaining with both markers was observed for nearly all centrosomes in control (row 1) or CHMP2A<sup>-</sup> (row 2) or VPS4B-depleted cells (row 3). (B) Confocal images of mitotic HeLa cells stained for two additional centrosomal markers (rabbit anti-Aurora A, green, *Left*; and mouse anti-Pericentrin, red, *Middle*; with the two images overlaid, *Right*), for control, CHMP2A<sup>-</sup>, or VPS4B-depleted cells as in A. Note that antibodies against Pericentrin in A and B were from different species and reacted with different epitopes, supporting the specificity of the centrosomal staining. (Scale bar =20  $\mu$ m.)



Table S1. siRNA sequences used in this study

Protein		First nucleotide	Sense sequence	RefSeq
CHMP1A	*	56	CCAAGAAGCGGAGAAGGAtt	NM_002768.2 Isoform 2
		102	GAAGGCCUUCUGCAGAAAtt	
	*	275	UGACCAAAGCCUGGACAAAtt	
CHMP1B		321	GGUCUCCUCAGUGAUGGActt	NM_020412.4
		92	CCGAAAAGGCCAAAAUUAAtt	
		131	ACAUGGAAGUUGCGAGGAUtt	
	*	176	AGAACCAGCGGUGAAUUUtt	
CHMP2A	*	344	UGGACAAAUCGAGCACCAtt	NM_014453.2
		54	CCAGAGGGCCUGAACCGUtt	
		324	GGCCAUGGGCACCAUGAACtt	
	*	395	AGGCAGAGAUCAUGGAUAUtt	
CHMP2B	*	464	AAGAUGAAGAGGAGUGAAtt	NM_014043.3
	*	45	GGAACAGAAUCGAGAGUUAAtt	
	*	93	UCGAGCAGCUUUGAGAAAAtt	
		208	AAACAGAAGACGAGAACUUtt	
CHMP3		405	GGAAAUGACUGAAGAAAUGtt	NM_016079.2 Isoform 1
		225	CAAGCUGUAUGCAUCCAAAAtt	
		276	GAACCAGCUCGGGUCUUGtt	
		353	UGAAGAUUCCAGAGAUUCAAtt	
		461	AGGAAGAAAUGGAGGAGAAAtt	
		515	UUACAGCAGGGCCUUGGGtt	
		531	GGGCAAAGCACCCAGUAAAAtt	
	*	209	CAAGGAAGGCUGUGAGCAAtt	
		323	CAGAAGUGAUGAAGGCCAUtt	
		382	AGGGAGUUGUCCAAAGAAAAtt	
CHMP4A	*	474	GGAAGAAGCAGAAAUGGAAAtt	NM_014169.2
	*	286	AAGUAUGGGACCAAGAAUAAtt	
	*	357	GGCACAAACUGACGGGACAAtt	
		681	AGAAGAACCUCAGUCAAAAtt	
		750	GGAUGAAGAUGAAGAAGCAAtt	
		306	GAGAGCUGCCUACAGGCUtt	
		186	UGAAGAAGCAAUACAGAAAAtt	
		215	CAGAGAAGAUACUGAUCAAAtt	
		433	GUCCUUCGUACCAUGGAGCtt	
		95	CGGAAGAGAUUUUAGCAAAtt	
CHMP4B	*	375	CGAUAAAGUUGAUGAGUUAAtt	NM_176812.4
		529	GACAAGAAUUUGCUGGAAAAtt	
	*	617	AGAAAGAAGAGGAGGACGAAtt	
CHMP4C	*	133	AAUCGAAUCCAGAGAGAAAAtt	NM_152284.3
		396	GCAAGAGAUCACAGAGCAAAtt	
	*	494	UGGCAGAACUUGAAGAAUUtt	
CHMP5		650	GGGCAGAAGAAGGGAUGAAtt	NM_016410.4
		116	AUGCUGAGCUAGUGAAGUAAtt	
		167	CUGCAAAGAAUUGGUCAAAtt	
		187	CAGAAAGCCUUGCGAGUUUtt	
		335	GAGUAAAGGAAAUGAAGAAAtt	
		80	GAGCAGAAUCCAUGACAAAtt	
	*	173	AGAAUUGGUCAAGCAGAAAtt	
	*	356	CAUACAAGCAAGUGAAGAUtt	
CHMP6		105	GAGGAUCGCCAGCAGCUGtt	NM_024591.4
		257	CCAUGGUUCAGAGUAUUGAAtt	
		284	AGAUCGAAAUGAAAGUGAUtt	
	*	319	GGAAAUGAGUGUCUGAACAtt	
		359	UUGAAGAGGUGGAGAGGAUtt	
		499	CAAAUAGAGCUGCCAGAGGtt	
		48	GGACAAGGCCAUCCUGCAAAtt	
	*	254	AGGCCAUGGUUCAGAGUAUtt	
		400	GUGGAGUACCAGCGGCAAAAtt	
		613	CAGAAGGAGAAGAGGGUCAAtt	
CHMP7	*	650	GGGAGAAGAUUGAAGUUtt	NM_152272.3
	*	784	GCAGAGAGGUGUAAAAGAGtt	
		812	GGGCAUGCCGAGCAGGAAAAtt	
VPS4A	*	200	CCGAGAAGCUGAAGGAUUAAtt	NM_013245.2

**Table S1. Cont.**

Protein		First nucleotide	Sense sequence	RefSeq
VPS4B	*	227	GCAAAGAGAAACACGGCAAtt	NM_004869.3
	*	425	CCAAAGAAGCACUGAAAGAtt	
	*	1,191	GGAUGUCCUGGAGAUAAAtt	
CEP55	*	43	GGAUCGAAGCCUAGUAACUtt	NM_018131.4 Isoform1
ALIX	*	417	CCUGGAUAAUGAUGAAGGAtt	NM_013374.4 Isoform1
LucGL2 (control1)			CGUACGCGGAAUACUUCGAtt	
QIANC (control2)			UUCUCGGAACGUGUCAGUtt	

**Table S2. Plasmid constructs**

Plasmid name	Internal ID	Backbone	Cloning sites	Epitope tags	Source
pQC.YFP.α-Tubulin	WISP08-204	pQCxIN	BamHI, MfeI/EcoRI	N,YFP	Clontech
pQC.H2B.mCherry	WISP08-205	pQCxIN	BamHI, MfeI/EcoRI	C,mCherry	HeLa genomic DNA
pGag-Pol	WISP07-127				1
pMD.G	WISP03-279				1
pCAG.MCS2.FOS	WISP08-103	pCAG.MCS			gift from Robert A. Lamb (Northwestern University, Evanston, IL)
pCAG.CHMP4C.FOS	WISP08-88	pCAG.MCS2	KpnI, XhoI	C,FLAG-One-5TRP	2

1. Onishi M, et al. (1996) Applications of retrovirus-mediated expression cloning. *Exp Hematol* 24:324–329.
2. von Schwedler UK, et al. (2003) The protein network of HIV budding. *Cell* 114:701–713.

**Table S3. Antibodies used for Western blotting**

Antigen	Source	Membrane	Blocking	Dilution	Source
CHMP1A	Rabbit	Nitrocellulose	0.5% milk	1/500	gift from Stanley M. Hollenberg (Oregon Health Sciences University, Portland, OR)
CHMP1B	Rabbit	PVDF	5.0% milk	1/250	UT592
CHMP2A	Rabbit	Nitrocellulose	0.5% milk	1/250	UT589
CHMP2B	Rabbit	PVDF	5.0% milk	1/1,000	Abcam (ab33174)
CHMP3	Rabbit	Nitrocellulose	0.5% milk	1/250	UT552
CHMP4A	Rabbit	PVDF	5.0% milk	2 µg/mL	Santa Cruz (H-52)
CHMP4B	Rabbit	Nitrocellulose	0.5% milk	1 µg/mL	Santa Cruz (C-12)
CHMP5	Rabbit	Nitrocellulose	0.5% milk	1/1000	gift from Diane McVey Ward (University of Utah, Salt Lake City, UT)
CHMP6	Rabbit	PVDF	5.0% milk	1/500	UT464
CHMP7	Goat	PVDF	5.0% milk	2 µg/mL	Santa Cruz (C-19)
VPS4A	Rabbit	PVDF	5.0% milk	1/500	UT289
VPS4B	Rabbit	PVDF	5.0% milk	1/500	UT292
FLAG	Mouse	PVDF	5.0% milk	0.2 µg/mL	Sigma-Aldrich (M2)
α-Tubulin	Mouse	PVDF	5.0% milk	1/5,000	Sigma-Aldrich (DM1A)
β-Actin	Rabbit	PVDF	5.0% milk	1/1,000	Bethyl Laboratories (A300-491A)

**Table S4. Antibodies used for immunofluorescence**

Antigen	Source	Fixation	Dilution	Source
VPS4A	Rabbit	Paraformaldehyde	1/25	UT289
VPS4B	Rabbit	Paraformaldehyde	1/25	UT292
Pericentrin	Rabbit	PFA or methanol	1/500	Novus Biological (NB100-68277)
Pericentrin	Mouse	Methanol	1/500	Abcam (ab28144)
Aurora A	Rabbit	Methanol	1/500	Abcam (ab12875)
γ-Tubulin	Mouse	Methanol	1/500	Sigma-Aldrich (GTU88)
α-Tubulin	Mouse	Paraformaldehyde	1/1000	Sigma-Aldrich (DM1A)







